FDA Investigator Natasha Gupta
Natasha Gupta has conducted inspections on 6 sites in 1 countries as of 21 Nov 2023. See below for a list of the FDA enforcement documents resulting from those inspections.
Investigator Details
Number of Inspected Sites:
6
Last Inspection Date:
21 Nov 2023
Investigator Role:
FDA Investigator
Redica ID:
Countries of Inspections:
United States of America
FDA Investigators that have inspected at least one site in common with Natasha Gupta:
Adetutu M Gidado,
Amy Chen,
Amy N Chen,
Anitha Palamakula Govada,
Annemarie Bodnar,
Atul J Agrawal,
Barbara Jwilimczyk Macri,
Daniel J Grabicki,
Daniel J Min,
David A Oluwo,
David L Chon,
Dr. Robert C Horan, MD,
Elaine E Gilfillan,
Elaine Gilfillan,
Gam S Zamil,
Guerlain Ulysse,
Jai P Singh,
Jeanne D Shaffer,
Johnny D Nwankwo,
Jose M Cayuela,
Joseph F Mcginnis, RPh,
Joy Rkozlowski Klena,
Juan Rjimenez Garcia,
Kenneth G Klobus,
Kenneth Nieves,
Ko U Min,
Liatte Kreuger, PharmD,
Marcellinus D Dordunoo,
Marcelo O Mangalindan, Jr,
Marcus A Ray,
Michael R Klapal,
Mindy M Chou,
Nancy M Espinal,
Nebil A Oumer,
Nicholas A Violand,
Olumide A Akinyemi,
Patrick C Klotzbuecher,
Paul L Bellamy,
Paula J Bretz,
Puspa Suresh Jayasekara,
Rachel C Harrington,
Regina T Brown,
Roseline N Boateng,
Russell J Glapion,
Samina S Khan,
Sena G Dissmeyer,
Stephanie L Shapley,
Tajah L Blackburn,
Tamil Arasu, PhD,
Unnee Ranjan,
Yaharn Su,
Young M Yoon
Natasha Gupta's Documents
Publish Date | Document Type | Title |
---|---|---|
October, 2022 | FDA 483 | Steri-Pharma LLC - Form 483, 2022-10-04 |
August, 2022 | EIR | New Dawn Manufacturing - EIR, 2022-08-29 |
March, 2022 | FDA 483 | Arnold Professional Pharmacy - Form 483, 2022-03-18 |
November, 2022 | FDA 483 | ChiRhoClin, Inc - Form 483, 2022-11-03 |
February, 2022 | FDA 483 | WES PHARMA INC - Form 483, 2022-02-18 |
May, 2022 | FDA 483 | Akorn Operating Company LLC (dba Akorn) - Form 483, 2022-05-17 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](https://redica.com/document-store/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more